Cancer Drug Comparisons Released By NCCN, Include Affordability
This article was originally published in The Pink Sheet Daily
The National Comprehensive Cancer Network unveils its first two sets of cancer drug comparisons, for multiple myeloma and chronic myelogenous leukemia, using graphical displays to help physicians and patients make treatment choices.
You may also be interested in...
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.